













June 8, 2022



The Honorable Charles Schumer Democratic Leader United States Senate Washington, D.C. 20510

The Honorable Mitch McConnell Republican Leader United States Senate Washington, D.C. 20510

Dear Leaders Schumer and McConnell:



We write in opposition to the 95 percent tax on prescription medicines contained in H.R. 5376, the "Build Back Better Act." The Senate should reject this harmful tax increase on the middle class, most notably seniors.



Section 139002 of the bill imposes a new excise tax of up to 95 percent on the gross sales of prescription medicines. The only way this tax can be avoided is if drug manufacturers submit to government-imposed price controls.



In a time of inflation levels not seen in many decades, the last thing Americans need to worry about is a new 95 percent tax on the prescription medicines they need to live healthy and fulfilling lives. A tax of this amount would nearly double the price of any prescription drug subject to it. It goes without saying that this tax would be faced by millions of Americans making far less than \$400,000 per year—the very people President Biden promised not to raise taxes on.



A price control to avoid the tax isn't a better option. Price controls have never worked throughout recorded human history. Without exception, they lead to scarcity and eventually government rationing. The end point of a price control is the government deciding who does and does not qualify for the scarce product or service. We believe that all Americans should have access to the prescription medicines they need free of government interference.



A 95 percent tax on prescription medicines under threat of price control is unnecessary. Since well before the Covid pandemic, net price growth for drugs have come in well under the general inflation rate. In fact, prescription drug prices increased around 1% in 2021, much lower than the 7% inflation rate Americans experienced during that same time period. A 95 percent drug tax and price control threat is a solution in search of a problem.

The United States is the world's leading developer of life-saving medicines, a fact highlighted during the COVID-19 pandemic. Both the 95 percent tax and price controls







will dry up funding for future research and development of new drugs. The next generation of innovative drugs should not be endangered by reckless government decisions today.



The 95 percent prescription drug tax is not serious healthcare or tax policy, and should be dropped.



Sincerely,

**Charles Sauer** Market Institute Naomi Lopez Goldwater



Brent Wm. Gardner Americans for **Prosperity** 

John Goodman Goodman Institute



Ryan Ellis Center for Free **Bob Carlstrom AMAC Action** 

Conservatives for **Property Rights**  Economy

Tom Schatz

Norm Singleton **US Policy** 

**Against Government** Waste

Council for Citizens

**Andrew Langer** Institute for Liberty

Lisa B. Nelson

Jim Martin 60 Plus Association

**TAXPAYERS** PROTECTION ALLIANCE **ALEC Action** 

Saul Anuzis

Adam Brandon FreedomWorks American Association of Senior Citizens

**Hadley Heath** Manning Independent Women's Voice Ashley Baker The Committee for Justice

**David Williams** 



Pete Sepp

**Taxpayers Protection Alliance** 

Americans for a Balanced Budget

Union **Grover Norquist** 

Americans For Tax

**National Taxpayers** 

**Richard Ralston** Americans for Free Choice in Medicine



Phil Kerpen American

Commitment

Reform

Twila Brase Citizens' Council for Health Freedom















AnneMarie Schieber Health Care News/Heartland Institute

Seton Motley Less Government

Dave Wallace Fair Energy Foundation

Jane Orient AAPS

James Edwards Conservatives for Property Rights

Larry Ward Constitutional Rights PAC

Joshua Delano Southeast Texans for Liberty

Richard Manning Americans for Limited Government

Terry Neese National Grassroots Network

Lovelynn Gwinn R.I.N.O Project

Autry Pruitt New Journey PAC

Melissa Ortiz Able Americans

Lisa Cathie MAGA Black George Landrith
Frontiers of Freedom

Paul Gessing Rio Grande Foundation

Christopher Sheeron Action for Health

Susan Carleson Carleson Center for Welfare Reform

Jeff Mazzella Center for Individual Freedom

Katie McAuliffe Digital Liberty

Bethany Marcum Alaska Policy Forum

Kevin Kearns US Business and Industry Council

John R. Toedtman Caesar Rodney Institute

Richard Walker Benjamin Rush Institute

Jonathan Imbody Faith Steps

John Hinderaker American Experiment

Andrew F. Quinlan Center for Freedom and Prosperity

















Rob Kenyon Virginia Republican Liberty Caucus

Mary Adams Maine Center Right Coalition

Ed Martin Eagle Forum Education and Legal Defense Fund

Mario H. Lopez Hispanic Leadership Fund

Annette Thompson Meeks Freedom Foundation of Minnesota

Lauren Daugherty Young Americans for Liberty

Sal Nuzzo James Madison Institute

Ralph Benko The Capitalist League

Julio Rivera Reactionary Times

Tom Giovanetti
Institute for Policy
Innovation

Kent Kaiser Trade Alliance to Promote Prosperity

Dee Stewart Americans for a Balanced Budget Ginevra Joyce-Myers Center for Innovation and Free Enterprise

Tom Hebert Open Competition Center

David Levien, MD, MBA, FACS American College of Healthcare Trustees

Casey Given Young Voices

Carla Howell Center for Small Government

Karen Kerrigan Small Business & Entrepreneurship Council

Yaël Ossowski Consumer Choice Center

Jenny Beth Martin Tea Party Patriots Action

James Davis Fans for Fair Pay

Jim Babka Downsize DC

Jason Vaughn Houston Young Republicans

Robert L. Maness GatorPAC



Morton Blackwell Conservative Leadership PAC



C. Preston Noell III Tradition, Family, Property, Inc.

Terry Wilcox Patients Rising Now

Paul Morinville RINO Reckoning

Donna Jackson Project 21



Palmer Schoening Family Business Coalition

Jeff Cargerman Inventors Project



Peter Thomas
Conservative Caucus

Dick Patten American Business Defense Council